Navigation Links
VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results
Date:11/8/2010

MOUNTAIN VIEW, Calif., Nov. 8, 2010 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS), a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today reported its financial results for the third quarter and nine months ended September 30, 2010.

Third Quarter HighlightsOn September 21, 2010, we announced top-line results from a two-year study of Qnexa which showed significant and sustained weight loss of greater than 10% over two years. Patients taking top- and mid-dose Qnexa achieved and maintained weight loss over two years of 11.4% and 10.4% of their initial body weight, respectively, as compared to placebo-treated patients with 2.5% weight loss (ITT-LOCF, p<0.0001). The findings come from the SEQUEL study (OB-305), a 52-week extension study for a subset of patients who completed the previously reported 56-week CONQUER study. The total study period was 108 weeks. SEQUEL included 675 obese or overweight patients, all of whom had two or more weight related co-morbidities, and an average baseline BMI of 36.1. Consistent with the first year experience, QNEXA therapy was well tolerated, with no new or unexpected adverse events. The most common side effects seen were constipation, tingling, dry mouth, altered taste and insomnia.

On October 1, 2010, we entered into a definitive asset purchase agreement with Meda to transfer our rights and assets related to MUSE, transurethral alprostadil, for the treatment of erectile dysfunction (ED).The acquisition price was $23.5 million, which includes an upfront cash payment of $22 million. The Company is eligible to receive a one-time milestone payment of $1.5 million based on future sales of MUSE. Meda has been our European distributor of MUSE since 2002. The assets sold include the United States and foreign MUSE patents, existing inventory and the manufacturing fa
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
2. VIVUS Announces Sale of MUSE Assets to Meda
3. VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
4. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
5. VIVUS to Present at Lazard Capital Markets Healthcare Conference
6. VIVUS Announces Promotion of Peter Tam to President
7. Data on VIVUS Qnexa to be Featured at European Association for the Study of Diabetes Annual Meeting
8. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
9. Results From Phase 3 EQUATE Trial of VIVUS Qnexa Highlighted at European Congress on Obesity
10. Anadys Pharmaceuticals Reports Third Quarter 2010 Financial Results and Highlights
11. GenVec Reports Third Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... , July 7, 2015 Sequent ... on developing innovative devices for the treatment of ... Kleine has joined its Board of Directors. ... years of medical device and healthcare industries experience. ... where he has commercialized numerous leading-edge products.  His ...
(Date:7/7/2015)... , July 7, 2015 Accelovance, ... focusing in Oncology, Vaccines, and General Medicine announced ... final locked database to Heron Therapeutics, Inc. for ... receptor antagonist product candidate SUSTOL® (granisetron injection, ... with the IV NK 1 receptor antagonist ...
(Date:7/7/2015)... Arentz Law Group is currently investigating cases of birth defects ... have taken Zyban while pregnant, and given birth to a ... the law firm immediately for a free legal consultation ... American Journal of Obstetrics & Gynecology  showed that mothers who ... birth to a child with " left outflow tract heart ...
Breaking Medicine Technology:Sequent Medical Appoints Mike Kleine to its Board of Directors 2Sequent Medical Appoints Mike Kleine to its Board of Directors 3Accelovance Completes Trial Enrollment and Delivery of Clinical Data for Heron Therapeutics' Phase 3 Trial 2Smoking cessation drug linked to birth defects when taken during pregnancy 2
(Date:7/7/2015)... ... 2015 , ... Illinois cannabis cultivation centers and dispensary owners ... The Medical Cannabis Alliance of Illinois’ (MCAI) board and its members have a ... making sure patients have access to cannabis as a viable medical treatment option. ...
(Date:7/7/2015)... ... July 07, 2015 , ... Catalent, ... development solutions for drugs, biologics and consumer health products, today announced that ... its antibody combination therapy (ACT) technology platform. The platform has the potential ...
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... Safe Catch ... every single fish for mercury. Albertsons, Gelson’s Markets, New Leaf Community Markets, Sprouts Farmers ... tuna. , “We developed the technology to test every fish for mercury,” said Safe ...
(Date:7/7/2015)... Rockville, Maryland (PRWEB) , ... July 07, 2015 ... ... mobile app to further enhance the experience for its patient community using its ... The app allows patients with primary immunodeficiency diseases (PI) to easily track their ...
(Date:7/7/2015)... ... July 07, 2015 , ... On Saturday, May 16th, 2015, ... the Manistee Golf and Country Club. Best Drug Rehabilitation staff members were delighted to ... helping underprivileged children. Kiwanis International, the parent of the Manistee Kiwanis Club, is a ...
Breaking Medicine News(10 mins):Health News:Cannabis Growers and Dispensaries Form Medical Cannabis Alliance of Illinois 2Health News:Catalent Biologics Adds New Technology Platform to Enable Antibody Combination Therapies 2Health News:Safe Catch Launches Tuna with Lowest Mercury Limit of Any Brand 2Health News:Get Real Health Launches New Mobile App for Immune Deficiency Foundation Patient Community 2Health News:Get Real Health Launches New Mobile App for Immune Deficiency Foundation Patient Community 3Health News:Best Drug Rehabilitation Team Participates in Kiwanis Club Golf Outing Fundraiser 2
... DETROIT, Aug. 25 Everyone can help save a life ... donor. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20071106/KARMANOSLOGO ) , ... 1:30 p.m., the Barbara Ann Karmanos Cancer Center, in collaboration with the ... increase participation in the Be The Match Registry, operated by the NMDP. ...
... , TUESDAY, Aug. 25 (HealthDay News) -- In a major ... that saliva contains at least 50 microRNAs that could aid ... in the saliva of 50 people with oral squamous cell ... microRNAs that may be associated with oral cancer. , The ...
... , DES MOINES, Iowa, Aug. 25 The ... Mary,s Medical Plaza II, a three-story, 70,000 square-foot medical office building ... new building located on the campus of Carondelet St. Mary,s Hospital, ... The offices currently include the Carondelet Medical Group, a large ...
... , Clearinghouse Served Hundreds of Community-Based Health Organizations ... A casualty of California Governor Arnold Schwarzenegger,s draconian cuts in ... The L.A. Gay & Lesbian Center, which operated the program ... of AIDS that all funding for it had been eliminated. , ...
... 2009 Minorities have poorer results and higher rates of ... from inside the carotid artery, according to a UT Southwestern ... in the journal Stroke. The multicenter study, ... journal, found that higher rates of poor surgical outcomes for ...
... National Eye Institute (NEI) and the Food and ... conference to determine how vision-related patient-reported outcomes might ... ophthalmology. Patient-reported outcomes are being incorporated more ... of evidence strongly suggests that such patient-reported outcomes ...
Cached Medicine News:Health News:Help Save a Life - Bone Marrow Donor Registry Drive Sept. 2 at the Karmanos Cancer Center 2Health News:Help Save a Life - Bone Marrow Donor Registry Drive Sept. 2 at the Karmanos Cancer Center 3Health News:Help Save a Life - Bone Marrow Donor Registry Drive Sept. 2 at the Karmanos Cancer Center 4Health News:Saliva May Help Spot Oral Cancer Early 2Health News:Schwarzenegger's Budget Cuts Force Closure of California AIDS Clearinghouse 2Health News:Minorities have poorer results, higher rates of inappropriate surgery to prevent stroke 2
Replacement bulb for Vibratome light system....
These specialty razor blades are feather thin and very sharp. Most users have found an increased quality level in Vibratome sections with these blades....
The care package includes a spare motor, fuse, Spare Fluorescent Bulb, additional Vibratome Feather Blades, Specimen Adhesive, Specimen Mounting Blocks, and a Specimen Tray....
... The Specimen Tray accessory fits inside the existing ... working area for tissue sectioning. Specimens are ... tray. This is a great option if ... expensive buffer, or wish to utilize the black ...
Medicine Products: